Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (252)
  2. Journal Article (103)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (4)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (381)
  2. Department of Medicine (381)
  3. Hematologic Malignancies Research (381)
  4. Hematologic Malignancies, Division of (381)
  5. Myeloma (381)
  6. Survivorship Research (225)

More Groups

People
  1. Hani Hassoun (202)
  2. Heather Landau (187)
  3. Sergio Giralt (185)
  4. David Chung (175)
  5. Neha Korde (174)
  6. Sham Mailankody (170)

More People

Years
  1. 2025 (12)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (41)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (12)

More Publications

Publishers
  1. American Society of Hematology (152)
  2. Elsevier Inc. (79)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (26)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (381)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI
    Meeting Abstract

    Usmani, S. Z.; Martin, T. G.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; Munshi, N. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Patel, K.; Sano, D.; Maris, M.; Lesokhin, A. M.; Von Keudell, G.; Doucette, K.; Ramchandren, R.; Pavlov, D.; Uger, R. A.; Molloy, N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma
    Meeting Abstract

    Patel, K.; Orlowski, R. Z.; Doucette, K.; Maris, M.; Pianko, M. J.; Ramchandren, R.; Stevens, D. A.; Vesole, D. H.; Uger, R. A.; Scheuber, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)
    Meeting Abstract

    Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodríguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1
    Meeting Abstract

    Jakubowiak, A. J.; Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating serum-free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save